Previous 10 | Next 10 |
2023-12-18 05:51:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edesa Biotech (NASDAQ: EDSA ) just reported results for the fourth quarter of 2023. Edesa Biotech reported earnings per share of -55 cents. This was above the analyst esti...
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provid...
Industrial & Commercial Bank of China Ltd. ADR (IDCBY) is expected to report for Q3 2023 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 Bexil Corp (BXLC) is expected to report for quarter end 2023-09-30 Timberline Resources Corp. (TLRS) is expected to report...
Edesa Biotech Inc. (EDSA) is expected to report $-0.71 for Q4 2023
2023-12-12 12:30:31 ET Gainers: C4 Therapeutics ( CCCC ) +85% . Aditxt ( ADTX ) +71% . Icosavax ( ICVX ) +48% . IN8bio ( INAB ) +31% . Petros Pharmaceuticals ( PTPI ) +31% . Clean Earth Acquisitions Corp ( CLIN ) +26% ...
2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-r...
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the 7 th Annual Dermatology...
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal to harmonize clinical trial designs in the U.S. ...
2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...
News, Short Squeeze, Breakout and More Instantly...
Edesa Biotech Inc. Company Name:
EDSA Stock Symbol:
NYSE Market:
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Health...